

IMPORTANT INFORMATION:

DISCONTINUATION OF SAXENDA® (LIRAGLUTIDE) IN AUSTRALIA



Dear Healthcare Professional,

We are writing to inform you that after careful consideration Novo Nordisk has made the decision to discontinue Saxenda® (liraglutide) in Australia.

This decision aligns with Novo Nordisk's commitment to providing our most effective and innovative treatment for people living with overweight and obesity, with Wegovy® (semaglutide 2.4 mg), our once-weekly treatment now available in Australia.^{1,2} In the STEP 8 head-to-head trial, Wegovy® 2.4 mg has demonstrated superior efficacy in weight loss, achieving an average weight reduction of 17%, compared to 7% with Saxenda®; gastrointestinal adverse events were reported by 84.1% with Wegovy® and 82.7% with Saxenda®.² This is a significant difference that highlights the effectiveness of Wegovy® for individuals seeking weight management solutions, alongside what it offers by way of benefits beyond weight loss as outlined by its additional indications in the Australian Product Information.¹

We encourage you to discuss alternative treatment options with patients currently using Saxenda®, including Wegovy® 2.4 mg, as the availability of Saxenda® will be in limited supply until December 2025. Saxenda® will not be available for purchase in Australia after December 2025.

Should you have any questions or need further information regarding this transition, please do not hesitate to contact our Medical Information Team at aunrccc@novonordisk.com or call 1800 668 626.

Reporting of safety information:

Adverse events relating to the use of any Novo Nordisk medicine should be reported to Novo Nordisk via aunrccc@novonordisk.com or the TGA.

Yours sincerely,

Dr Ana Svensson

Vice President, Clinical, Medical, Regulatory & Pharmacovigilance

TGA: Therapeutic Goods Administration

References: **1.** Wegovy® (semaglutide 2.4 mg) Approved Product Information. Available at: <https://rss.medsinfo.com.au/no/pi.cfm?product=nopwegov>. **2.** Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508T.

PBS Information:

Saxenda® and Wegovy® are not listed on the PBS.

Please review full Product Information before prescribing, available at:

Saxenda® Product Information:
<https://rss.medsinfo.com.au/no/pi.cfm?product=nopsaxen>

Wegovy® Product Information:
<https://rss.medsinfo.com.au/no/pi.cfm?product=nopwegov>

- ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Novo Nordisk Pharmaceuticals Pty Ltd. Level 10, 118 Mount Street, North Sydney NSW 2060. ABN 40 002 879 996. Novo Nordisk Medical Information (Australia) 1800 668 626. www.novonordisk.com.au. ® Registered trademark of Novo Nordisk A/S. AU25SX00011. May 2025.